Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-02-15
2001-02-13
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S106000
Reexamination Certificate
active
06187787
ABSTRACT:
BACKGROUND OF THE INVENTION
Intercalation is one of several modes by which drugs interact with DNA wherein a planar portion of the drug is inserted in between adjacent stacked base pairs of a double stranded DNA. The intercalation process results in helix extension and unwinding of the DNA. Included within these drugs are antitumor agents, actinomycin D, adriamycin and daunomycin, as well as several drugs for treatment of parasitic disease including ethidium bromide, quinacrine, chloroquine and miracil D. U.S. Pat. No. 2,441,665 discloses a class of alkylene diamine derivatives which are valuable as antimalarial agents. U.S. Pat. No. 2,113,357 discloses basically substituted amino-acridine derivatives useful in treating blood parasites.
More recently, DNA intercalating ligands have been proposed for use in targeting alkylating agents to DNA by attachment of the intercalating ligand to the alkylating agent. Gourdie et al.
J. Med. Chem.
1991 34:240-248.
Since the biological properties of these DNA intercalating drugs are believed to result from their binding, researchers have focused efforts on designing molecules that have a high affinity for DNA. Planar polycyclic aromatic molecules show a strong propensity to bind to DNA by intercalation. Jaycox et al.
J. Heterocyclic Chem.
1987 24:1405-1408. In recent years, efforts to identify molecules with a greater affinity and selectivity for DNA have resulted in the development of bifunctional intercalating agents in which two intercalating ligands are bridged by a central linking chain. In general, enhanced binding is observed with molecules of this type. Canellakis et al.
Biochim. Biophys. Acta,
1976 418:277; Becker and Dervan,
J. Am. Chem. Soc.
1979 101:3664; and Wakelin et al.
Med. Res. Rev.
1986 6:275. However, the chemical and physical nature of the linking chain has been found to play a major role in the binding process.
A homologous series of diacridines containing two 9-aminoacridine chromophores linked via a simple methylene chain were studied in order to investigate the minimum interchromophore separation required to permit bifunctional intercalation. Wakelin et al.
Biochemistry
1978 17:5057. Viscometric, sedimentation and electric dichroism experiments showed that compounds having one to four methylene groups in the linker are restricted to monofunctional intercalation whereas bifunctional interaction was observed when the chain length was increased to six methylene groups or more. Accordingly, the transition in functionality was concluded to lie between interchromophore distances of 6.3 and 8.8 angstroms.
Additional studies however, indicate that the nature of the bridging chain and/or substituents on the acridine ring has a profound effect on the ability of diacridine compounds to act as bifunctional intercalating agents. DNA binding characteristics of a number of acridine dimers of which two aromatic rings, each ring being the monomeric 2-methoxy-6-chloro-9-(3-dimethyl amino propylamino acridine), were linked by a chain of varying length and structure were also determined . Le Pecq et al.
Proc. Nat'l Acad. Sci. USA
1975 72(8):2915-2919. The linking chains of these acridine dimers include: —(CH
2
)
3
—NH—(CH
2
)
4
—NH—(CH
2
)
3
—(IIA); —(CH
2
)
3
—NH—(CH
2
)
4
(IIB); and (CH
2
)
3
—NH—(CH
2
)
3
(III). It was found that the 2 dimers with the longest chain length, (IIA) and (IIB), bisintercalated while only one of the two rings of the dimer with the shortest chain (III) of 9 angstroms was intercalated. Bisintercalative binding of a bis(acridine) derivative specifically designed as a relatively rigid molecule in which the two chromophores are essentially coplanar and 7 angstroms apart in the only reasonably strain-free conformation has also been reported. Atwell et al.
J. Am. Chem. Soc.
1985 107:4335-4337.
In contrast, bis-intercalators bridged by flexible chains have generally exhibited reduced affinities for DNA, in part because of self stacking interactions which compete with the binding process. Barbet et al.
Biochemistry
1976 15:2642; and Capelle et al.
Biochemistry
1979 18:3354. Further, bis-intercalation can introduce undesirable entropic effects when a flexible linker is forced into an extended chain conformation. Jaycox et al.
J. Heterocyclic Chem.
1987 24:1405-1408. In addition, it is a concern that flexible bis-intercalators can creep in a stepwise fashion along the DNA macromolecule, thereby lowering ligand residence lifetimes at any one site. Denny et al.
J. Med. Chem.
1985 28:1568. Such a process could have significant effects on efficacy of these intercalators as anticancer agents as residence lifetimes have been correlated with in vivo antitumor activity for a large number of DNA intercalators. Feigon et al.
J. Med. Chem.
1984 27:450. Studies by Jaycox et al. indicate that it is the rigid tether framework and not the aromatic character of the linking chain that is responsible for the cytotoxic action of DNA intercalating agents.
J. Heterocyclic Chem.
1987 24:1405-1408.
In the present invention a series of novel bis-acridinyl DNA intercalating agents with semi-flexible linking chains have been prepared and demonstrated to be tight binders of DNA and to have antitumor activity.
SUMMARY OF THE INVENTION
An object of the present invention is to provide compounds of formula (I)
wherein Z comprises a linear arrangement of at least three aromatic rings or two acyclic rings arranged in a 1,4 or 1, 3 configuration.
Another object of the present invention is to provide a method of inhibiting cancer cells which comprised contacting the cells with a compound of formula (I).
Yet another object of the present invention is to provide a method of treating cancer in a patient which comprises administering to the patient an effective amount of a compound of formula (I) so that growth of the cancer is inhibited.
DETAILED DESCRIPTION OF THE INVENTION
A series of compounds have been synthesized which are represented by formula (I)
wherein Z comprises a linear arrangement of at least three aromatic rings or two acyclic rings arranged in a 1,4 or 1,3 configuration. In a preferred embodiment, Z is selected from a group consisting of
in either a cis—cis, cis-trans, or trans—trans configuration,
U.S. Pat. No. 2,503,889 discloses halogenated diacridine compounds with similar linking chains.
The compounds of the present invention have been demonstrated to bind DNA in a tighter fashion than DNA intercalation agents currently in clinical use for the treatment of cancer. In addition, the compounds of the present invention have been demonstrated to be more effective inhibitors of cancer cells than bis(9-aminoacridines) disclosed in the prior art. Accordingly, it is believed that the compounds of the present invention will be useful in treating patients suffering from cancer.
In one embodiment, compounds of the present invention are synthesized from the condensation of 9-chloroacridine with selected diamines in a molten phenol solution and isolated via flash chromatography. Preferably, the diamine comprises the formula:
wherein X is either —O—, —CH
2
—, —CH
2
—CH
2
—, or CH═CH. However, as will be obvious to those of skill in the art upon this disclosure, other means of synthesis can be used.
The compounds of the present invention were demonstrated to have increased DNA binding affinity. Thermal denaturation studies were performed on calf thymus DNA. Addition of the compounds of the present invention to the calf thymus DNA caused the denaturation temperature to increase approximately 11° C. (see Table 1).
Further, these compounds were demonstrated to have inhibitory activity against cancer cells. Using the methodologies disclosed by Jaycox et al.
J. Heterocyclic. Chem.
1987 24:1405-1408, the compounds of the present invention were tested for their ability to exhibit cytotoxicity in the murine leukemia cell line (L1210). A number of intercalating agents currently in clinical use for treatment of cancer were also evaluated in this assay for comparison. ID50 values (the concentration which inhibits
Gribble Gordon W.
Jaycox Gary D.
Mosher Michael
Huang Evelyn Mei
Law Offices of Jane Massey Licata
Trustees of Dartmouth College
LandOfFree
Bis(9-aminoacridine) DNA intercalating agents having... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bis(9-aminoacridine) DNA intercalating agents having..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bis(9-aminoacridine) DNA intercalating agents having... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2579898